Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up.

MLA

Mathers, John C., et al. “Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-Up.” Cancer Prevention Research (Philadelphia, Pa.), vol. 15, no. 9, Sept. 2022, pp. 623–34. EBSCOhost, https://doi.org/10.1158/1940-6207.CAPR-22-0044.

APA

Mathers, J. C., Elliott, F., Macrae, F., Mecklin, J.-P., Möslein, G., McRonald, F. E., Bertario, L., Evans, D. G., Gerdes, A.-M., Ho, J. W. C., Lindblom, A., Morrison, P. J., Rashbass, J., Ramesar, R. S., Seppälä, T. T., Thomas, H. J. W., Sheth, H. J., Pylvänäinen, K., Reed, L., … Burn, J. (2022). Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up. Cancer Prevention Research (Philadelphia, Pa.), 15(9), 623–634. https://doi.org/10.1158/1940-6207.CAPR-22-0044

Chicago

Mathers, John C, Faye Elliott, Finlay Macrae, Jukka-Pekka Mecklin, Gabriela Möslein, Fiona E McRonald, Lucio Bertario, et al. 2022. “Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-Up.” Cancer Prevention Research (Philadelphia, Pa.) 15 (9): 623–34. doi:10.1158/1940-6207.CAPR-22-0044.